Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

Psoriatic Arthritis

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study

Arthritis Rheumatol

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB

doi: 10.1002/art.70092

Rheumatoid Arthritis

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Arthritis Res Ther

Picchianti Diamanti A, Paci V, Luchetti Gentiloni MM, Salemi S, Sesti G, Bellofatto IA, Baldi C, Falsetti P, Chimenti MS, D'Antonio A, Crepaldi G, Zabotti A, Giovannini I, Canzoni M, Fiore D, Sebastiani GD, Scirocco C, Perricone C, Laganà B, Iagnocco A

doi: 10.1186/s13075-025-03671-z

Psoriatic Arthritis

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open

Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L

doi: 10.1136/rmdopen-2025-005522

Psoriatic Arthritis

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Ann Rheum Dis

Kivitz A, Baraliakos X, Muensterman ET, Kavanaugh A, van der Heijde D, Klimiuk PA, Valenzuela G, Dokoupilova E, Poirier G, Srivastava B, Dasen S, Zhang X, Hong T, Chen J, Pothula P, Weng HH, Trivedi M, Lertratanakul A

doi: 10.1016/j.ard.2025.05.023

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Rheumatoid Arthritis

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Ann Rheum Dis

Taylor PC, Mease PJ, de Vlam K, Mpofu S, Wetzel D, Stevens AM, Wiens B, Koskinen LO, Ohlman S, Feldwisch J, Frejd FY, Brun NC, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F

doi: 10.1016/j.ard.2025.02.019

Rheumatoid Arthritis

Fibroblast-Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) - an observational study protocol

BMJ Open

Xenophontos M, Baldeweg FC, Ross R, Rutter-Locher Z, Hill S, Ryan S, Ali Awadelkareem M, Law ST, Bennett DL, Buckley CD, Humby F, Kirkham BW, Denk F, Taams LS

doi: 10.1136/bmjopen-2024-097892

Systemic Lupus Erythematosus

Secukinumab in active lupus nephritis: Results from phase III, randomised, placebo-controlled study (SELUNE) and open-label extension study

Rheumatology (Oxford)

Zhao MH, Cons Molina F, Aroca G, Tektonidou MG, Mathur A, Tangadpalli R, Sun R, Martin R, Pellet P, Ngoc Phuong Huynh T

doi: 10.1093/rheumatology/keaf536

Psoriatic Arthritis

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set

Ann Rheum Dis

Charlton RA, Gates E, Coates LC, Galloway J, McHugh N, McGrogan A, Hackett S, Brooke M, Cavill C, Tillett W

doi: 10.1016/j.ard.2025.02.020

Related content

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Fibroblast-Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) - an observational study protocol

Secukinumab in active lupus nephritis: Results from phase III, randomised, placebo-controlled study (SELUNE) and open-label extension study

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set